{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:11:42Z","timestamp":1792080702442,"version":"4.4.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":1493,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030831","name":"Novartis Pharma K. K","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100030831","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Sodium glucose co-transporter 2 inhibitors have diuretic effects in both patients with glycosuria and with natriuresis. We sought to assess the effect of luseogliflozin on estimated plasma volume (ePV) in patients with type 2 diabetes and heart failure with preserved ejection fraction (HFpEF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This study was a post-hoc analysis of the MUSCAT-HF trial (UMIN000018395), a multicentre, prospective, open-label, randomized controlled trial that assessed the effect of 12 weeks of luseogliflozin (2.5 mg, once daily, n = 83) as compared with voglibose (0.2 mg, three times daily, n = 82) on the reduction in brain natriuretic peptide (BNP) in patients with type 2 diabetes and HFpEF. The analysis compared the change in ePV calculated by the Straus formula from baseline to Weeks 4, 12, and 24, using a mixed-effects model for repeated measures. We also estimated the association between changes in ePV and changes in other clinical parameters, including BNP levels. Luseogliflozin significantly reduced ePV as compared to voglibose at Week 4 {adjusted mean group-difference \u22126.43% [95% confidence interval (CI): \u22129.11 to \u22123.74]}, at Week 12 [\u22128.73% (95%CI: \u221211.40 to \u22126.05)], and at Week 24 [\u221211.02% (95%CI: \u221213.71 to \u22128.33)]. The effect of luseogliflozin on these parameters was mostly consistent across various patient clinical characteristics. The change in ePV at Week 12 was significantly associated with log-transformed BNP (r = 0.197, P = 0.015) and left atrial volume index (r = 0.283, P = 0.019).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Luseogliflozin significantly reduced ePV in patients with type 2 diabetes and HFpEF, as compared with voglibose. The reduction of intravascular volume by luseogliflozin may provide clinical benefits to patients with type 2 diabetes and HFpEF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.13683","type":"journal-article","created":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T05:19:50Z","timestamp":1635916790000},"page":"712-720","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effects of Luseogliflozin on Estimated Plasma Volume in Patients with Heart Failure with Preserved Ejection Fraction"],"prefix":"10.1093","volume":"9","author":[{"given":"Mitsutaka","family":"Nakashima","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Miyoshi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Ejiri","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558 ,","place":["Japan"]},{"name":"Department of Internal Medicine, Tamano City Hospital , Okayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Kihara","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kihara Cardiovascular Clinic , Asahikawa ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Hata","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Minamino Cardiovascular Hospital , Hachioji ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Nagano","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Iwasa Hospital , Gifu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takaishi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Mitoyo General Hospital , Kanonji ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Toda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558 ,","place":["Japan"]},{"name":"Department of Internal Medicine, Okayama East Neurosurgery Hospital , Okayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Nanba","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Okayama Rosai Hospital , Okayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Specified Clinic of Soyokaze CardioVascular Medicine and Diabetes Care , Matsuyama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Akagi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Akaiwa Medical Association Hospital , Okayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Sakuragi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Iwakuni Clinical Center , Iwakuni ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Minagawa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Minagawa Cardiovascular Clinic , Gifu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kawai","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama City Hospital , Okayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Nishii","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558 ,","place":["Japan"]},{"name":"Department of Internal Medicine, Yoshinaga Hospital , Bizen ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Fuke","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Japanese Red Cross Okayama Hospital , Okayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Yoshikawa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuyama City Hospital , Fukuyama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazufumi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"MUSCAT-HF Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,3]]},"reference":[{"key":"2026012114182295300_ehf213683-bib-0001","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"key":"2026012114182295300_ehf213683-bib-0002","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1388-9842(03)00162-4","article-title":"Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure","volume":"5","author":"Matsumori","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"2026012114182295300_ehf213683-bib-0003","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026012114182295300_ehf213683-bib-0004","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026012114182295300_ehf213683-bib-0005","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. carvedilol heart failure study group","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"2026012114182295300_ehf213683-bib-0006","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"2026012114182295300_ehf213683-bib-0007","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012114182295300_ehf213683-bib-0008","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012114182295300_ehf213683-bib-0009","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur Heart J"},{"key":"2026012114182295300_ehf213683-bib-0010","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur Heart J"},{"key":"2026012114182295300_ehf213683-bib-0011","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"2026012114182295300_ehf213683-bib-0012","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026012114182295300_ehf213683-bib-0013","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"2026012114182295300_ehf213683-bib-0014","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med."},{"key":"2026012114182295300_ehf213683-bib-0015","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114182295300_ehf213683-bib-0016","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jacc.2019.11.036","article-title":"Clinical benefit of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026012114182295300_ehf213683-bib-0017","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"key":"2026012114182295300_ehf213683-bib-0018","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1111\/dom.13855","article-title":"Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes","volume":"21","author":"Dekkers","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2026012114182295300_ehf213683-bib-0019","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1111\/dom.14387","article-title":"Association of estimated plasma volume and weight loss after long-term administration and subsequent discontinuation of the sodium-glucose cotransporter-2 inhibitor tofogliflozin","volume":"23","author":"Matsubayashi","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2026012114182295300_ehf213683-bib-0020","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12933-021-01295-6","article-title":"Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial","volume":"20","author":"Tanaka","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2026012114182295300_ehf213683-bib-0021","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2213-8587(20)30382-X","article-title":"Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial","volume":"9","author":"Jensen","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026012114182295300_ehf213683-bib-0022","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015103","article-title":"Effect of luseogliflozin on heart failure with preserved ejection fraction in patients with diabetes mellitus","volume":"9","author":"Ejiri","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026012114182295300_ehf213683-bib-0023","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-026590","article-title":"The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial","volume":"9","author":"Ejiri","year":"2019","journal-title":"BMJ Open"},{"key":"2026012114182295300_ehf213683-bib-0024","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.cardfail.2018.07.462","article-title":"Calculated estimates of plasma volume in patients with chronic heart failure-comparison with measured volumes","volume":"24","author":"Fudim","year":"2018","journal-title":"J Card Fail"},{"key":"2026012114182295300_ehf213683-bib-0025","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1172\/JCI102501","article-title":"Water diuresis produced during recumbency by the intravenous infusion of isotonic saline solution","volume":"30","author":"Strauss","year":"1951","journal-title":"J Clin Invest"},{"key":"2026012114182295300_ehf213683-bib-0026","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","article-title":"Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial","volume":"143","author":"Nassif","year":"2021","journal-title":"Circulation"},{"key":"2026012114182295300_ehf213683-bib-0027","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00392-020-01794-8","article-title":"Estimated plasma volume status in heart failure: clinical implications and future directions","volume":"110","author":"Kobayashi","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"2026012114182295300_ehf213683-bib-0028","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.jchf.2015.06.014","article-title":"Prognostic value of estimated plasma volume in heart failure","volume":"3","author":"Duarte","year":"2015","journal-title":"JACC Heart Fail"},{"key":"2026012114182295300_ehf213683-bib-0029","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/jamacardio.2018.2568","article-title":"Association of natriuretic peptides with cardiovascular prognosis in heart failure with preserved ejection fraction: secondary analysis of the TOPCAT randomized clinical trial","volume":"3","author":"Myhre","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2026012114182295300_ehf213683-bib-0030","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1136\/heartjnl-2018-314173","article-title":"Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction","volume":"105","author":"Salah","year":"2019","journal-title":"Heart"},{"key":"2026012114182295300_ehf213683-bib-0031","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ejhf.1494","article-title":"Heart failure Association of the European Society of cardiology practical guidance on the use of natriuretic peptide concentrations","volume":"21","author":"Mueller","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012114182295300_ehf213683-bib-0032","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2026012114182295300_ehf213683-bib-0033","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur Heart J"},{"key":"2026012114182295300_ehf213683-bib-0034","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13683","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13683","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/1\/712\/65375251\/eschf_9_1_712.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/1\/712\/65375251\/eschf_9_1_712.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:21:42Z","timestamp":1769023302000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/9\/1\/712\/8326348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,3]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,11,3]]},"published-print":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13683","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2]]},"published":{"date-parts":[[2021,11,3]]},"assertion":[{"value":"2021-08-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}